These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 18308679)
1. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study: response to Porcellati et al. Banarer S Diabetes Care; 2008 Mar; 31(3):e16; author reply e17. PubMed ID: 18308679 [No Abstract] [Full Text] [Related]
2. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Porcellati F; Rossetti P; Busciantella NR; Marzotti S; Lucidi P; Luzio S; Owens DR; Bolli GB; Fanelli CG Diabetes Care; 2007 Oct; 30(10):2447-52. PubMed ID: 17623819 [TBL] [Abstract][Full Text] [Related]
3. Insulin detemir (levemir), a new long-acting insulin. Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022 [TBL] [Abstract][Full Text] [Related]
4. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir. Peterson GE Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343 [TBL] [Abstract][Full Text] [Related]
5. Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial. Danne T; Datz N; Endahl L; Haahr H; Nestoris C; Westergaard L; Fjording MS; Kordonouri O Pediatr Diabetes; 2008 Dec; 9(6):554-60. PubMed ID: 18761644 [TBL] [Abstract][Full Text] [Related]
6. Insulin detemir: new drug. A second long-acting insulin analogue: many uncertainties, few advantages. Prescrire Int; 2006 Oct; 15(85):163-7. PubMed ID: 17121210 [TBL] [Abstract][Full Text] [Related]
7. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus. Wutte A; Plank J; Bodenlenz M; Magnes C; Regittnig W; Sinner F; Rønn B; Zdravkovic M; Pieber TR Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):461-7. PubMed ID: 17647145 [TBL] [Abstract][Full Text] [Related]
8. Insulin detemir, does a new century bring a better basal insulin? Hordern SV; Russell-Jones DL Int J Clin Pract; 2005 Jun; 59(6):730-9. PubMed ID: 15924603 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes. Hompesch M; Ocheltree SM; Wondmagegnehu ET; Morrow LA; Kollmeier AP; Campaigne BN; Jacober SJ Curr Med Res Opin; 2009 Nov; 25(11):2679-87. PubMed ID: 19761358 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes. Porcellati F; Rossetti P; Ricci NB; Pampanelli S; Torlone E; Campos SH; Andreoli AM; Bolli GB; Fanelli CG Diabetes Care; 2007 May; 30(5):1261-3. PubMed ID: 17303785 [No Abstract] [Full Text] [Related]
11. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Monami M; Marchionni N; Mannucci E Diabetes Res Clin Pract; 2008 Aug; 81(2):184-9. PubMed ID: 18495286 [TBL] [Abstract][Full Text] [Related]
12. Humalog--a new insulin analogue. Drug Ther Bull; 1997 Aug; 35(8):57-8. PubMed ID: 9350086 [No Abstract] [Full Text] [Related]
13. Potential flaws and biases in a randomized controlled trial (RCT) of insulin determir vs. insulin glargine by Pieber and colleagues. Alcolado J; Poole CD; Peters JR; Currie CJ Diabet Med; 2008 Jan; 25(1):115-6. PubMed ID: 18199142 [No Abstract] [Full Text] [Related]
14. Insuline glusine (Apidra): a new rapid-acting insulin. Med Lett Drugs Ther; 2006 Apr; 48(1233):33-4. PubMed ID: 16625142 [TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes. Koehler G; Treiber G; Wutte A; Korsatko S; Mader JK; Semlitsch B; Pieber TR Diabetes Obes Metab; 2014 Jan; 16(1):57-62. PubMed ID: 23841569 [TBL] [Abstract][Full Text] [Related]
16. Insulin degludec's ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes. Biester T; Blaesig S; Remus K; Aschemeier B; Kordonouri O; Granhall C; Søndergaard F; Kristensen NR; Haahr H; Danne T Pediatr Diabetes; 2014 Feb; 15(1):27-33. PubMed ID: 24467565 [TBL] [Abstract][Full Text] [Related]
17. A comparison of pharmacokinetics and pharmacodynamics of biphasic insulin aspart 30, 50, 70 and pure insulin aspart: a randomized, quadruple crossover study. Thorisdottir RL; Parkner T; Chen JW; Ejskjaer N; Christiansen JS Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):216-21. PubMed ID: 19175369 [TBL] [Abstract][Full Text] [Related]
19. Inhaled insulin (exubera). Med Lett Drugs Ther; 2006 Jul; 48(1239):57-8. PubMed ID: 16841019 [No Abstract] [Full Text] [Related]
20. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes. Baxter MA Acta Diabetol; 2008 Dec; 45(4):253-68. PubMed ID: 18766296 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]